Skip to content
PeptideAI
Observationalskin

SNAP-8

A longer Argireline with two extra residues that bind the SNARE complex more tightly, usually formulated alongside its shorter parent.

Also known as Acetyl Octapeptide-3, Acetyl Octapeptide-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, SNAP-8

Observational — Human data without randomisation. Suggestive, and easily confounded.

SNAP-8's clinical numbers come from unpublished manufacturer panels. The SNARE mechanism is solid biochemistry; whether enough peptide reaches the muscle from a topical product has never been demonstrated independently.

How it works

SNAP-8 adds Ala-Asp to the Argireline hexapeptide, restoring more of the native SNAP-25 N-terminal sequence. In vitro this gives measurably stronger competition for the position SNAP-25 occupies during SNARE zippering, so the docking complex is less stable and fewer acetylcholine vesicles fuse at the endplate. The practical problem is unchanged and arguably worse: at 1075 Da and highly charged, transdermal delivery to a mimetic muscle is very poor, so whatever happens clinically is happening at a fraction of the concentration used in the cell assays. Manufacturer in-vivo panels report roughly a 35% reduction in wrinkle depth at 10% of the trade solution over 28 days.

Targets: SNAP-25, SNARE complex assembly, Neuromuscular acetylcholine release

Dosing

ProtocolDoseFrequencyRoute
Standard expression-line serumMorning and night to clean skin, applied before heavier creams.—twice dailytopical
  • · Trade solutions are used at 5-10% of the formula, which is roughly 0.05-0.1% actual peptide since SNAP-8 is supplied as a ~1% aqueous solution. From raw powder, 0.05-0.1% w/w is the target.

Cycling

Continuous use; effects wash out within weeks of stopping.

Work out your exact syringe units →

Pharmacology

Half-life
Not established; degraded by skin peptidases within hours.
Onset
About 4 weeks of twice-daily use for the first visible change.
Routes
topical
Molecule
Synthetic acetylated octapeptide amide
Sequence length
8 amino acids
Molecular weight
1075.2 Da

Handling

Diluent
Distilled or deionised water
Typical mix
20 or 50 mL
Vial sizes
50, 100, 200 mg
Lyophilised
Sealed, cool and dry; freezer for long-term.
Reconstituted
Refrigerated and preserved; use unpreserved aqueous solutions within a few weeks.

Mixing

Freely water soluble. 100 mg into 100 mL of base gives 0.1%.

Side effects

  • uncommonMild dryness or transient tightness

Combining it

  • synergyargireline — The standard pairing — same target, different affinity and size profile.
  • synergysyn-ake — Presynaptic SNARE blockade plus postsynaptic nicotinic receptor antagonism; the two halves of the junction.
  • redundantbotulinum-toxin-type-a — Adds nothing over an already-treated muscle.

What to monitor

  • · Photographs in full expression, same lighting, at 0 and 8 weeks.

Legal status

Cosmetic ingredient (INCI Acetyl Octapeptide-3) approved worldwide.

References

  • Lubrizol/Lipotec SNAP-8 technical dossier (other)

Mechanism in depth

SNAP-8 exists because of a straightforward structure-activity observation: if a six-residue copy of the SNAP-25 N-terminus competes for its slot in the SNARE complex, an eight-residue copy that reproduces more of the native sequence should compete better. In cell-free assays it does. The extra Ala-Asp restores contacts that the hexapeptide lacks, and the reported affinity for the SNARE assembly site is higher. That is real medicinal chemistry and it would matter a great deal if this were an injectable. Topically it runs into the same wall as Argireline, only harder, because every residue you add makes the molecule bigger and more charged. There is a general rule in transdermal delivery — sometimes called the 500 Dalton rule — that passive permeation of intact skin becomes negligible above roughly 500 Da, and while it is a rule of thumb rather than a law, both of these peptides are well past it. Improving target affinity does nothing for a molecule that never reaches the target. The manufacturer's headline number, roughly 35% wrinkle-depth reduction at 10% of the trade solution over 28 days, comes from unpublished in-vivo panels with no vehicle control. As with Argireline, the plausible non-neuromuscular explanation is stratum corneum hydration from a highly charged, strongly hygroscopic peptide sitting in the outer layer, and nobody has done the experiment that would separate the two.

What usually goes wrong

The trade-solution confusion is worse here than with Argireline because SNAP-8 is typically supplied at around 1% rather than 5%, so the arithmetic differs from what people are used to. A '10% SNAP-8' product contains roughly 0.1% peptide. Someone working from raw powder who targets 10% has made something a hundred times more concentrated than any panel, which is the usual route to a stinging face and nothing else. The second failure is buying it as a stronger Argireline. On paper it binds better; in skin it penetrates worse; the net is unknown and probably not favourable. Third, as with the whole neurotransmitter-peptide group, judging it without standardised photographs in full expression.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
Degraded by skin peptidases. N-terminal acetylation and C-terminal amidation block exopeptidase attack, which is why it is formulation-stable for years.
Elimination
No meaningful systemic exposure from topical use.

Receptor targets

  • SNAP-25 N-terminal binding site within the assembling SNARE complex — Reported as higher than Argireline's in supplier in-vitro work; no published Kd

    Competitive destabilisation of SNARE zippering, reducing calcium-dependent acetylcholine vesicle fusion. Reversible.

  • Stratum corneum water binding — Not a receptor interaction

    The mechanism most likely responsible for whatever visible smoothing occurs.

What to expect, and when

Week 4: manufacturer panels report first change at 28 days. Week 8-12: whatever plateau you reach. Discontinuation: reversal within one to two weeks, consistent with a hydration effect rather than a neuromuscular one.

Stacking and comparisons

Chemically compatible with everything. It is almost always co-formulated with Argireline, on the argument that two affinities at one site are better than one — which is not how competitive binding at a single site works, but the combination is harmless and cheap. The more coherent stack is SNAP-8 with a postsynaptic blocker like Syn-Ake or Vialox, because those genuinely act at a different point of the junction. Just recognise that you are combining several compounds that share the same unsolved delivery problem. If you want a topical routine that reliably does something to expression lines, the honest answer is that no combination of these peptides substitutes for toxin, and the money is better spent on a structural peptide plus a retinoid.

Against Argireline, SNAP-8 has the better in-vitro affinity, the worse molecular weight, no independent trial of any kind, and a price premium. Argireline at least has Blanes-Mira and an FDA penetration study. Against botulinum toxin, the same category error described in the Argireline entry applies. Against Syn-Ake and Vialox, SNAP-8 is presynaptic and those are postsynaptic, which makes the combination mechanistically non-redundant even though all three share the same delivery failure.

Rough cost

$10–$55/month. Raw acetyl octapeptide-3 powder runs roughly $30-70 per gram, more expensive than Argireline. Finished products $12-55 a month. Market observation, not a sourced pricing study.

Genuinely uncertain

  • No penetration study of acetyl octapeptide-3 has ever been published. The comparison with Argireline's measured figures is inference from molecular weight and charge.
  • The reported affinity advantage over Argireline is from supplier in-vitro work with no published Kd.
  • The 35% wrinkle-depth reduction figure is from unpublished uncontrolled manufacturer panels and should not be treated as a trial result.
  • The molecular weight of 1075.2 Da in the Core record is plausible for the acetylated amidated octapeptide but I could not confirm it against a primary source.
  • No independent human trial of SNAP-8 exists in any form.

Papers